• 1
    National Institutes of Health. National Institutes of Health State of the Science Conference statement on manifestations and management of chronic insomnia in adults, June 13–15, 2005. Sleep 2005; 28: 104957.
  • 2
    Kim K, Uchiyama M, Okawa M et al. An epidemiological study of insomnia among the Japanese general population. Sleep 2000; 23: 417.
  • 3
    Leger D, Guilleminault C, Dreyfus JP et al. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000; 9: 3542.
  • 4
    Ohayon MM, Caulet M, Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997; 20: 71523.
  • 5
    Ohayon MM, Zulley J, Guilleminault C et al. How age and daytime activities are related to insomnia in the general population: consequences for older people. J Am Geriatr Soc 2001; 49: 3606.
  • 6
    Montgomery P, Dennis J. Cognitive behavioural interventions for sleep problems in adults aged 60+. Cochrane Database Syst Rev 2003; Issue 1: CD003161.
  • 7
    Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999; 22(Suppl. 2): S38693.
  • 8
    Glass J, Lanctot KL, Herrmann N et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331: 1169.
  • 9
    Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 36574.
  • 10
    Morgan K, Tomeny M. Benzodiazepine withdrawal and rebound insomnia. Acta Psychiatr Scand 1989; 80: 2978.
  • 11
    Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2011; Issue 1: CD008502.
  • 12
    Vermeeren A, Coenen AM. Effects of the use of hypnotics on cognition. Prog Brain Res 2011; 190: 89103.
  • 13
    Sateia MJ, Nowell PD. Insomnia. Lancet 2004; 364: 195973.
  • 14
    Poyares D, Guilleminault C, Ohayon MM et al. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 2004; 38: 32734.
  • 15
    Dubocovich ML, Yun K, Al-Ghoul WM et al. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J 1998; 12: 121120.
  • 16
    Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48: 30110.
  • 17
    Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006; 63: 114957.
  • 18
    Erman M, Seiden D, Zammit G et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7: 1724.
  • 19
    Richardson GS, Zammit G, Wang-Weigand S et al. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009; 70: 46776.
  • 20
    Griffiths R, Suess P, Johnson M. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep 2005; 28: A44.
  • 21
    Mets MA, de Vries JM, de Senerpont Domis LM et al. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects. Sleep 2011; 34: 132734.
  • 22
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (text revision). Washington, DC: American Psychiatric Association, 2000.
  • 23
    Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
  • 24
    Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 62934.
  • 25
    Uchiyama M, Hamamura M, Kuwano T et al. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 2011; 12: 11926.
  • 26
    Uchimura N, Ogawa A, Hamamura M et al. Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study. Expert Rev Neurother 2011; 11: 21524.
  • 27
    Mayer G, Wang-Weigand S, Roth-Schechter B et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32: 35160.
  • 28
    Zammit G, Erman M, Wang-Weigand S et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3: 495504.
  • 29
    Roth T, Seiden D, Sainati S et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7: 3128.
  • 30
    Roth T, Seiden D, Wang-Weigand S et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23: 100514.
  • 31
    Zammit G, Wang-Weigand S, Rosenthal M et al. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med 2009; 5: 3440.
  • 32
    Gooneratne NS, Gehrman P, Gurubhagavatula I et al. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study. J Clin Sleep Med 2010; 6: 57280.
  • 33
    Gross PK, Nourse R, Wasser TE. Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study. J Clin Sleep Med 2009; 5: 2833.
  • 34
    Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol 2006; 46: 1408.
  • 35
    Kryger M, Roth T, Wang-Weigand S et al. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath 2009; 13: 7984.
  • 36
    Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath 2007; 11: 15964.
  • 37
    McElroy SL, Winstanley EL, Martens B et al. A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. Int Clin Psychopharmacol 2011; 26: 4853.
  • 38
    Markwald RR, Lee-Chiong TL, Burke TM et al. Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. Sleep 2010; 33: 82531.
  • 39
    Zee PC, Wang-Weigand S, Wright KP Jr et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med 2010; 11: 52533.
  • 40
    Zammit G, Schwartz H, Roth T et al. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med 2009; 10: 559.
  • 41
    Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28: 3037.
  • 42
    Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol 2009; 24: 10311.
  • 43
    Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5: 17784.
  • 44
    Foley DJ, Monjan AA, Brown SL et al. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995; 18: 42532.
  • 45
    Wang-Weigand S, McCue M, Ogrinc F et al. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis. Curr Med Res Opin 2009; 25: 120913.